NKG2D/NKG2-Ligand Pathway Offers New Opportunities in Cancer Treatment

• Published in: Frontiers in immunology Vol. 10; p. 661
• Main Authors: Frazao, Alexandra, Rethacker, Louise, Messaoudene, Meriem, Avril, Marie-Françoise, Toubert, Antoine, Dulphy, Nicolas, Caignard, Anne
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 29.03.2019
• Subjects: Immunology; natural killer cells; NKG2D; NKG2D CARs; NKG2D ligands; tumor immunosurveillance; NKG2D CARs; natural killer cells; NKG2D; tumor immunosurveillance; NKG2D ligands
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2019.00661

The antitumor functions of NK cells are regulated by the integration of positive and negative signals triggered by numerous membrane receptors present on the NK cells themselves. Among the main activating receptors, NKG2D binds several stress-induced molecules on tumor targets. Engagement of NKG2D by its ligands (NKG2D-Ls) induces NK cell activation leading to production of cytokines and target cell lysis. These effects have therapeutic potential as NKG2D-Ls are widely expressed by solid tumors, whereas their expression in healthy cells is limited. Here, we describe the genetic and environmental factors regulating the NKG2D/NKG2D-L pathway in tumors. NKG2D-L expression is linked to cellular stress and cell proliferation, and has been associated with oncogenic mutations. Tumors have been found to alter their to NKG2D-L expression as they progress, which interferes with the antitumor function of the pathway. Nevertheless, this pathway could be advantageously exploited for cancer therapy. Various cancer treatments, including chemotherapy and targeted therapies, indirectly interfere with the cellular and soluble forms of NKG2D-Ls. In addition, NKG2D introduced into chimeric antigen receptors in T- and NK cells is a promising tumor immunotherapy approach.